• Explore /
  • Poster
  • / A phase 1a/b study of BR101801, a PI3K γ/δ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.

A phase 1a/b study of BR101801, a PI3K γ/δ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.

Abstract Poster

Authors

Bong-Seog Kim

Bong-Seog Kim

Boryung Corporation., Seoul, South Korea

Bong-Seog Kim , Seok Jin Kim , Tae Min Kim , Dok Hyun Yoon , Jin Seok Kim , Eunyoung Lee , Won-Sik Lee , Jeong-Ok Lee , Deok-Hwan Yang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04018248

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7551)

DOI

10.1200/JCO.2023.41.16_suppl.7551

Abstract #

7551

Poster Bd #

102

Abstract Disclosures

Similar Posters

First Author: Krish Patel

First Author: Krish Patel

First Author: Dejan Juric

First Author: Manish R. Patel